- Good Sleep Can Make You Feel Young
- U.S. Mpox Cases Rising Again as Vaccinations Lag
- Binge Drinking Boosts Heart Risks, Especially for Women
- Too Often, Nearby Defibrillators Go Unused on People in Cardiac Arrest
- Stressed? Some Genes Could Raise Your Heart Attack Risk
- Puerto Rico Declares Dengue Epidemic as Cases Climb
- Hormonal Meds for Birth Control, Menopause Linked to Brain Tumors
- These 3 Factors Make Your Brain More Vulnerable to Dementia
- High Rate of Suicidal Thoughts Among Black Men in Rural America: Study
- Just 30 Minutes Less Sitting Time Per Day Cuts Seniors’ High Blood Pressure
Orbactiv Approved for Drug-Resistant Skin Infections
The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.
The drug is sanctioned to treat methicillin-resistant Staphylococcus aureus (MRSA) and other acute bacterial skin infections. It’s the third such drug approved in 2014, following May approval of Dalvance (dalbavancin) and June approval of Sivextro (tedizolid), the FDA said.
Orbactiv’s safety and effectiveness were evaluated in two clinical studies involving almost 2,000 adults. The most common side effects included headache, nausea, vomiting, skin abscesses on the arms and legs, and diarrhea.
The drug’s label will include a boxed warning that it could interact with the blood-thinning medication warfarin, the agency said.
Orbactiv is marketed by The Medicines Company, based in Parsippany, N.J.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.